Synaptiq Therapeutics has launched as a privately held clinical-stage biotechnology company after acquiring SYN-001, formerly known as NB-001, from Nobias Therapeutics. Announced on July 23, 2026, the transaction places the investigational oral therapy in a newly created company that plans to conduct a Phase IIb trial in children and adolescents experiencing neuropsychiatric symptoms associated with 22q11.2 deletion syndrome.
The financial terms were not disclosed, leaving the amount of capital committed to the programme and the expected development runway unclear. Synaptiq Therapeutics said the planned trial would be conducted at specialist centres in North America and Europe, supported by an investor and operational consortium that includes Arctic Therapeutics, Investcorp-backed Sanos Group and an Icelandic investment fund managed by AxUM Securities. Nobias Therapeutics will retain an equity interest in the new company, while Patrick Dougherty has been appointed chief executive officer.
The launch provides SYN-001 with a dedicated corporate structure, clinical-development infrastructure and new financial sponsors. It does not, however, alter the maturity of the existing evidence. The completed Phase 2 study produced an encouraging safety profile and signals of possible clinical activity, but its principal overall efficacy comparison did not cross the conventional threshold for statistical significance. The central test for Synaptiq Therapeutics is therefore whether a larger, better targeted Phase IIb study using a disease-specific outcome measure can produce a reproducible and clinically interpretable treatment effect.
What exactly has Synaptiq Therapeutics acquired from Nobias Therapeutics?
SYN-001 is fasoracetam monohydrate, an investigational small molecule described as a non-stimulant modulator of multiple metabotropic glutamate receptors. Nobias Therapeutics had been developing the compound as NB-001 for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome, including problems involving attention, anxiety and social communication. The United States Food and Drug Administration’s orphan-drug database lists fasoracetam monohydrate as designated for the treatment of 22q11.2 deletion syndrome, while also confirming that it has not been approved for that orphan indication.
The new company said it acquired the lead programme, while the former Nobias Therapeutics website states that substantially all of the company’s assets were acquired by Synaptiq Therapeutics. The broader asset language may indicate that Synaptiq received supporting intellectual property, development records and programme-related infrastructure alongside the drug candidate, although a detailed transaction breakdown has not been published.
Synaptiq’s structure is unusual in that several founding participants can contribute directly to clinical execution. Arctic Therapeutics is expected to provide drug-development capabilities, scientific expertise and relationships with the Center for Applied Genomics at the Children’s Hospital of Philadelphia. Sanos Group, which operates clinical research, biostatistics, trial-supply and patient-recruitment businesses, is expected to support preparation and execution of the multinational Phase IIb study.
This arrangement could allow Synaptiq Therapeutics to function with a relatively focused internal organisation while drawing on established external infrastructure. That may reduce the time required to rebuild vendor networks and site relationships after the asset transfer. It does not remove the need for adequate financing, consistent manufacturing, regulatory documentation and independent oversight of a trial involving a heterogeneous paediatric rare-disease population.
What did the completed Phase 2 trial really establish about SYN-001?
The completed study, registered as NCT05290493, enrolled 37 children and adolescents aged six to 17 years with molecularly confirmed 22q11.2 deletion syndrome and clinically meaningful neuropsychiatric symptoms. It used a randomised, placebo-controlled crossover design in which participants received six weeks of NB-001 and six weeks of placebo, separated by a one-week washout period. Participants, caregivers, investigators, site personnel and outcome assessors were blinded to treatment sequence.
Participants received a total daily dose of 400 milligrams, administered as two 100-milligram capsules twice daily. The study’s primary objective was safety and tolerability, not confirmatory efficacy. Nobias Therapeutics reported that the most frequent adverse events were fatigue and nasopharyngitis, each affecting 9% of participants, while epistaxis, fever and vomiting were reported in 6%. The company said adverse events were mild or moderate and that no serious adverse event was attributed to treatment.
Those findings support continued clinical investigation, but meeting a safety-focused primary endpoint should not be interpreted as proof that SYN-001 improves neuropsychiatric symptoms. The key efficacy comparison used the Clinical Global Impression-Improvement scale. The least-squares mean score was 3.34 during active treatment and 3.69 during placebo, producing a difference of minus 0.36 and a reported p-value of 0.07. Because lower scores represent greater improvement, the numerical result favoured NB-001, but it did not meet the commonly used p-value threshold of 0.05.
Nobias also reported that responder rates were between 1.4 and 1.7 times higher during active treatment than during placebo and that improvements were observed across attention-deficit/hyperactivity disorder, anxiety and autism-related symptom groups. The company described the trial as signal-finding and not statistically powered to establish efficacy. The 2026 Synaptiq announcement additionally referred to statistically significant improvements in clinically relevant subgroups, although it did not provide subgroup sizes, effect estimates, multiplicity controls or enough detail to determine how robust those analyses were.
Subgroup findings can be valuable for designing later studies, particularly in a disorder with considerable variation in symptoms and severity. However, results from small subgroups can also be unstable and may reflect baseline imbalances or repeated testing. The Phase IIb trial will therefore need to prespecify the population, primary analysis and subgroup strategy rather than relying on retrospective identification of participants who appeared more likely to respond.
Why will the new CGI-I-22q scale be central to the next SYN-001 trial?
One of the programme’s biggest challenges is that 22q11.2 deletion syndrome does not produce a single uniform neuropsychiatric presentation. Some children may experience pronounced inattention, others may have anxiety or social-communication difficulties, and many show clinically important symptoms across several domains without satisfying the full diagnostic threshold for one conventional psychiatric disorder. Updated clinical recommendations describe 22q11.2 deletion syndrome as a complex multisystem condition requiring coordinated evaluation and management of developmental, behavioural and psychiatric manifestations.
Nobias Therapeutics reported in June 2025 that it had reached preliminary alignment with the United States Food and Drug Administration on the possible use of a global assessment of improvement, together with a key secondary clinical outcome, as registrational endpoints. The company proposed a condition-specific Clinical Global Impression-Improvement measure called CGI-I-22q, designed to capture symptom domains considered particularly relevant to people with 22q11.2 deletion syndrome.
The planned Phase IIb trial is expected to use mean change on the CGI-I-22q as its primary efficacy endpoint. Nobias had also planned an independent study to generate preliminary evidence supporting the scale’s measurement properties and an objective assessment of attention and executive function to help select a key secondary measure for later development. Synaptiq’s latest announcement indicates that the disease-specific scale will be incorporated into the new trial, although the final protocol, sample size and statistical analysis plan have not been publicly disclosed.
A tailored scale could improve sensitivity by measuring changes that generic instruments fail to capture. It could also reduce noise created by combining children with different symptom profiles. The regulatory and scientific risk is that a new clinician-reported measure must demonstrate content validity, reliability, consistency between raters and a relationship to changes that are meaningful to patients and caregivers.
The planned Phase IIb study must therefore do more than produce a favourable average score. It needs to show that the scale behaves predictably across sites, countries, languages and symptom presentations. Rater training, blinded central review, control of placebo response and prespecified handling of missing data will be particularly important because global impression measures depend partly on clinical judgement.
Does SYN-001’s glutamate-receptor mechanism provide meaningful differentiation?
SYN-001 is described as a modulator or activator of multiple metabotropic glutamate receptors. Glutamate signalling has an important role in neuronal communication, cognition and behaviour, making the pathway scientifically relevant to several neurodevelopmental and neuropsychiatric conditions. The programme’s oral, non-stimulant profile may also be attractive in a population where symptoms can span attention, anxiety and social functioning.
Mechanistic plausibility, however, is not evidence of clinical benefit. Neuropsychiatric symptoms associated with genetic syndromes can reflect numerous biological, developmental and environmental factors, and modulation of a relevant pathway does not guarantee a measurable improvement in daily functioning. The Phase 2 findings provide a reason to continue investigation, but not a basis for concluding that the glutamatergic mechanism has been clinically validated.
The crossover design offered efficiency in a very small rare-disease population because each participant received both active treatment and placebo. It also introduced interpretive considerations, including the adequacy of the one-week washout period, possible period effects and the potential influence of caregiver expectations. A conventional parallel-group Phase IIb design could provide a cleaner estimate of treatment effect, although Synaptiq Therapeutics has not yet disclosed the intended allocation model.
Longer treatment and follow-up may also be needed. The previous study evaluated each treatment condition over only six weeks, which may be sufficient to detect some behavioural changes but is unlikely to establish durability or longer-term tolerability. A future regulatory package will probably require evidence that any observed improvement persists and translates into benefits that matter in home, educational or social settings.
How significant is the unmet need in 22q11.2 deletion syndrome?
22q11.2 deletion syndrome, sometimes referred to as DiGeorge syndrome or velocardiofacial syndrome, is caused by a deletion in a section of chromosome 22. Clinical manifestations vary widely and can include congenital heart disease, immune dysfunction, palatal abnormalities, endocrine complications, learning difficulties and psychiatric illness. Estimates of prevalence vary partly because the syndrome is believed to be underdiagnosed, particularly among people without immediately recognisable congenital abnormalities.
Synaptiq Therapeutics estimates that approximately 65,000 people in the United States live with the condition. The company said anxiety, attention-deficit/hyperactivity disorder and autism-related manifestations can materially affect educational achievement, social functioning and family life. There is currently no therapy approved specifically for the neuropsychiatric manifestations of 22q11.2 deletion syndrome, with care generally directed toward each individual’s diagnosed symptoms and multidisciplinary needs.
The competitive environment has also changed. Harmony Biosciences had investigated transdermal cannabidiol, known as ZYN002, in children and adolescents with 22q11.2 deletion syndrome. In January 2026, Harmony said it was no longer pursuing the indication after reviewing results from the separate Phase 3 RECONNECT study in Fragile X syndrome. That decision removes one potential late-stage competitor, although it also illustrates the difficulty of demonstrating consistent treatment effects in heterogeneous neurobehavioural conditions with substantial placebo responses.
A therapy specifically labelled for this genetically defined population could have strategic value even within a relatively small market. Genetic confirmation can support patient identification, specialist treatment centres can assist recruitment, and orphan-drug development may allow a focused commercial model. At the same time, diagnosis remains fragmented, symptom severity varies substantially, and payers would likely require evidence that treatment produces a meaningful functional benefit rather than only a modest change on a clinician-rated scale.
What must Synaptiq Therapeutics prove before SYN-001 becomes a credible late-stage asset?
The first measurable milestone will be publication or registration of the Phase IIb protocol. Investors, clinicians and rare-disease specialists will be looking for the number and age of participants, trial duration, dose selection, randomisation model, inclusion criteria, primary endpoint definition and prespecified key secondary outcome. The company must also explain how it will manage participants with different combinations of anxiety, attention and social-communication symptoms.
The second requirement is transparent validation of the CGI-I-22q instrument. Preliminary regulatory alignment is helpful, but it is not regulatory approval of the drug, confirmation that the endpoint has been fully validated or a guarantee that a positive study will be sufficient for a marketing application. The scale must demonstrate that it can reliably distinguish a genuine treatment effect from rater variability, placebo response and normal behavioural fluctuation.
The third issue is funding. Transaction terms and financing amounts were not disclosed, making it difficult to assess whether Synaptiq Therapeutics has enough capital to complete a multinational Phase IIb study, perform required manufacturing work and prepare for a registrational programme. The involvement of clinical-development specialists may improve operational efficiency, but rare-disease trials involving children, specialised raters and geographically dispersed centres can still be expensive and time-consuming.
Synaptiq Therapeutics has given SYN-001 a more focused home and assembled partners capable of moving the programme forward. Its next study will determine whether that corporate restructuring has rescued a promising but still uncertain asset or merely transferred the same evidentiary challenge to a new balance sheet. The decisive result will not be another subgroup signal. It will be a prespecified, adequately powered improvement that can be reproduced across patients, clinicians and trial sites while retaining an acceptable safety profile.